Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Multimodal Biomarkers for Diagnosis and Prognosis in Cerebral Amyloid Angiopathy
Authors not listed
National Taiwan University Hospital · 2018
Abstract
By combination of plasma (Aβ40, Aβ42, total tau, and phosphorylated tau, etc.), genetic (ApoE ε2 or ε4 allele), MRI (cerebral perfusion, microbleeds, cortical superficial siderosis, enlarged perivascular space, etc.) and PET imaging (amyloid and tau) biomarkers, the study aims to
1. Enhance the diagnostic potentials of the radiological biomarkers by combining MRI and amyloid PET in CAA patients.
2. Investigate the biological pathogenesis in CAA patients using the less invasive plasma biomarkers and to correlate with structural and function imaging, including MRI, amyloid and tau imaging.
3. Study the characteristics of long-term progression of amyloid deposition in CAA patients using the radiological, biochemical and genetic biomarkers.
4. Study the prognosis predicting markers.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Anonymous. (2018). Multimodal Biomarkers for Diagnosis and Prognosis in Cerebral Amyloid Angiopathy. <em>National Taiwan University Hospital</em>. https://clinicaltrials.gov/study/NCT03969732
Vancouver
Anonymous. Multimodal Biomarkers for Diagnosis and Prognosis in Cerebral Amyloid Angiopathy. National Taiwan University Hospital. 2018.
BibTeX
@misc{anon2018Multim,
title = {Multimodal Biomarkers for Diagnosis and Prognosis in Cerebral Amyloid Angiopathy},
author = {Anonymous},
journal = {National Taiwan University Hospital},
year = {2018},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Annals of Neurology 2017
Preprint · OA
Age, vascular health, and Alzheimer disease biomarkers in an elderly sample
Journal of Proteomics 2016
Preprint · OA
Multicentric study of the effect of pre-analytical variables in the quality of plasma samples stored in biobanks using different complementary proteomic methods
Jonsson Comprehensive Cancer Center 2025
Open access · US-GOV
A Phase Ib Open Label Clinical Trial to Evaluate the Safety and Efficacy of ERAS-801 in Recurrent Glioblastoma or Elderly Newly Diagnosed Glioblastoma Patients With EGFR Amplification and/or Mutation (ERAS-801-3.0)
Ashvattha Therapeutics, Inc. 2023
Open access · US-GOV
A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers
Istituto Nazionale di Ricovero e Cura per Anziani 2025
Open access · US-GOV
Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER): a Multicenter, Observational, 3-arms, Prospective Study
Innovation in Aging 2021
Open access · CC-BY